TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria~* Diagnosis of advanced malignancy, nonsmall-cell lung cancer (NSCLC) only during stage 1 of accrual.~* Nonsynonymous mutation of B-RAF or DDR2, defined as follows:.~  i) NSCLC with inactivating B-RAF mutation.~ii) NSCLC with discoidin domain receptor 2 (DDR2) mutation.~iii) Malignancy of other histology with DDR2 mutation or inactivating B-RAF mutation, or NSCLC having a B-RAF mutation that is not functionally characterized.~* At least 1 target lesion per Response Evaluation Criteria in Solid Tumors, vol 1.1, on baseline staging evaluation.~* Disease progression after ≥ 1 prior treatment regimen.~Exclusion Criteria~* Pleural or pericardial effusion, Grade \>1.~* QTcF \>470 msec (Grade ≥2) or diagnosed congenital long QT syndrome.~* Absolute granulocyte count \<1500/mm\^3.~* Hemoglobin level \<10 g/dL.~* Platelet count \< 75,000/mm\^3.~* Serum calcium level \<institutional lower limit of normal.~* Hypokalemia, hypophosphatemia, or hypomagnesemia, Grade \>1, despite supplementation.~* Creatinine \>3\*institutional upper limit of normal (ULN).~* Total bilirubin level \>1.5\*ULN.~* Alanine transaminase level \>3\*ULN.~* Other protocol-defined Inclusion/Exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation) (Type: EXPERIMENTAL): Participants with nonsmall-cell lung cancer (NSCLC) and an inactivating B-RAF mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
- Dasatinib, 140 mg (NSCLC With DDR2 Mutation) (Type: EXPERIMENTAL): Participants with NSCLC and a discoidin domain receptor 2 (DDR2) mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of metastatic or locally recurrent colorectal carcinoma~* Aged 18 years or older~* Paraffin embedded histological material available for analysis~* Either confirmed loss of expression of MSH2 on immunohistochemistry IHC or confirmed mutation in MSH2 on gene sequencing~* Life expectancy of \> 3 months~Exclusion Criteria:~* Previous treatment with methotrexate, either for malignant or non-malignant disease, except when methotrexate was given at low dose with other drugs to modify their effects~* Concomitant uncontrolled medical conditions~* Concomitant metastatic malignancy apart from non-melanotic skin cancers and carcinoma in situ of the uterine cervix in the last 10 years~* Any contraindication to treatment with methotrexate (as this will affect safety)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must have histologically or cytologically confirmed Wild Type NSCLC that is stage IV / metastatic or recurrent~2. Participants must have received at least one prior systemic therapy that was not an anti-PD-1, anti-PD-L1 and/or anti-CTLA-4 treatment for the advanced stage of the disease~3. Participants with tumor tissue low expression of PD-L1 as defined by Tumor Proportion Score (TPS) 0% - 49%~4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~5. Participants with measurable disease by spiral computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumor (RECIST) v.1.1 criteria~6. Participants that have completed prior radiotherapy or radiosurgery at least 2 weeks prior to randomization~Exclusion Criteria:~1. Participants with active central nervous system (CNS) metastases or carcinomatous meningitis~2. Participants with any serious or uncontrolled medical disorder or active infection with the hepatitis virus or the human immunodeficiency virus (HIV)~3. Participants with Grade 1 (NCI-CTCAE v.4.03) toxicities attributed to prior anti-cancer therapy (other than alopecia and fatigue) prior to randomization~4. Participants that have received nivolumab~5. Participants that have received therapy with anti-tumor vaccines or other immuno-stimulatory antitumor agents~6. Participants with a history of severe hypersensitivity reactions to monoclonal antibodies~7. Participants that have received therapy with anti-PD-1, anti-PD-L1, anti-PD-L-2, anti-CD-137, and/or anti CTLA-4 antibodies~8. Participants receiving any investigational agent within 28 days of first administration of trial treatment~9. Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pegilodecakin+Nivolumab (Type: EXPERIMENTAL): Participants received Pegilodecakin subcutaneously at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (\>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.~Nivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every 2 weeks (Q2W), or 480 mg every 4 weeks (Q4W).
- Nivolumab (Type: ACTIVE_COMPARATOR): Participants received Nivolumab on day 1 of each 14- or 28- day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every two weeks (Q2W), or 480 mg every 4 weeks (Q4W).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of DMD confirmed~* Ambulant~* Corticosteroid therapy for at least one year prior to study day 1 and on a stable dose and schedule for at least 6 months prior to study day 1~* Evidence of muscle weakness by clinical assessment~Exclusion Criteria:~* Any previous treatment with another investigational product within 6 months prior to study day 1~* Any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease that is not related to DMD~* Inability to perform a whole body dual x-ray absorptiometry (DXA) scan

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACE-031 0.5 mg/kg q4wk (Type: EXPERIMENTAL): None
- ACE-031 1.0 mg/kg q2wk (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Active CLL (as defined by the National Cancer Institute Working Group)~* Patients must have received at least one prior therapy for CLL and have been treated with a nucleoside analogue.~* Recruitment will be limited to those with an ECOG performance status of 2 or less.~Exclusion Criteria:~* Patients who are pregnant or breastfeeding~* Patients with a history of autoimmune cytopenias~* Patients with platelets \< 50 x 109/L or an absolute neutrophil count \< 1.5X109/L~* Patients with hepatic disease or an AST/ALT 6x above the upper limit of normal~* Patients with a calculated creatinine clearance \< 30 ml/min using the Cockroft and Gault formula~* Patients with a history of pancreatitis~* Patients who are receiving drugs that affect VPA protein binding or metabolism~* Patients with active infection, HIV or active viral hepatitis~* Patients with active secondary malignancy or who have central nervous system involvement with CLL~* Patients diagnosed with more an aggressive lymphoproliferative disorder such as Richter's transformation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Paced Dyssynchrony and Myocardial Perfusion IN apiCal Hcm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, \>18 years.~2. HCM patients with apical HCM defined as apical hypertrophy with apical LV systolic obliteration and the presence of characteristic ECG changes. Participants with a mixed cardiac phenotype will be considered if they also meet these criteria and do not have resting outflow tract obstruction.~3. A programmable intracardiac pacing device with a right atrial lead and an apically / low septal located right ventricular lead.~4. Willing and able to provide informed consent.~Exclusion Criteria:~1. Outflow tract obstruction \>50 mmHg at rest due to systolic anterior mitral movement.~2. Evidence of high-grade heart block.~3. Moderate or severe primary valvular disease.~4. Unrevascularised, known, significant coronary disease: the significance of any known coronary disease will be determined after discussion with an independent clinician.~5. Atrial fibrillation at the time of randomisation.~6. Inability to undergo CMR with adenosine stress and gadolinium contrast imaging.~7. Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active ventricular pacing (Type: ACTIVE_COMPARATOR): Asynchronous dual chamber pacing (DOO mode) at a heart rate just higher than that expected to be achieved with adenosine infusion (same rate in each arm)
- Back-up ventricular pacing (Type: PLACEBO_COMPARATOR): Asynchronous atrial pacing with intrinsic ventricular activation (AOO mode) at a heart rate just higher than that expected to be achieved with adenosine infusion (same rate in each arm)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia~* CGI-S score of 4 or less at baseline~Exclusion Criteria:~* Concurrent antipsychotic treatment~* Treatment with antidepressants or mood stabilizers within 2 weeks of randomization~* Acute exacerbation of schizophrenia within 3 months of baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): None
- Arm B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Clinically confirmed cerebellar ataxia with a SARA total score ≥ 3 (range 0-40).~* 2. Clinical diagnosis of probable or possible MSA-C.~* 3. Patients older than 18 years old and younger than 80 years old.~Exclusion Criteria:~* 1. Major systemic diseases such as hepatic, renal or heart failure, malignancy, stroke.~* 2. Concomitant medication which inhibit CYP2C19 enzyme such as Clopidogrel, cimetidine, fluconazole, ketoconazole, voriconazole, etravirine, fluoxetine, fluvoxamine, ticlopidine.~* 3. Pregnancy and/or breastfeeding.~* 4. Acute diseases that might interfere with the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tllsh2910 to placebo (Type: EXPERIMENTAL): Tllsh2910 160mg per day for 12 weeks with wash-out period 12 weeks and subsequent placebos for 12 weeks.
- Placebo to Tllsh2910 (Type: EXPERIMENTAL): Placebos for 12 weeks with wash-out period 12 weeks and subsequent Tllsh2910 160mg per day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Endotracheal Cardiac Output Monitor (ECOM) for Patients Undergoing Liver Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing liver transplantation surgery~Exclusion Criteria:~* Patients who are anticipated to remain intubated postoperatively for greater than 24 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- OLT patients intubated with ECOM ETT (Type: None): Patients undergoing liver transplantation and intubated with ECOM endotracheal tube (ETT).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Elastography in Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infants \< 6 months of age~* Known liver disease based (liver enzymes, bilirubin, and/or GGT at least twice the upper limit of normal for age)~* Parental/LAR permission obtained~Exclusion Criteria:~* Standard MRI exclusion criteria as set forth by the CCHMC Division of Radiology~* Severe coagulopathy (INR \> 3 or platelets \<50,000)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- MRI with MRE (Type: EXPERIMENTAL): Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Pulmonary Vein Isolation Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Indication for open-heart surgery: Mitral valve repair or replacement, evidence of a dilated left atrium~Exclusion Criteria:~* History of Atrial Fibrillation~* Need for emergent cardiac surgery~* Previous cardiac surgery~* Preoperative need for an intraaortic balloon pump or intravenous inotropes~* Current diagnosis of active endocarditis~* Mental impairment/or experience other conditions which may not allow subject to understand nature~* Significance and scope of study~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation.
- 2 (Type: NO_INTERVENTION): The control group of patients will undergo operation for mitral valve disease without the additional Pulmonary Vein Isolation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the rectum~  * Locally advanced (T3-4 Nx) or metastatic (T2 N+ M1) synchronous disease~    * Metastases must be resectable~ * Primary tumor examined by endorectal echography and MRI~* Measurable disease by thoraco-abdomino-pelvic scanner~* Disease considered susceptible to treatment with radiotherapy and chemotherapy~* No diffuse metastases considered nonresectable~* No acute occlusion not caused by colostomy~PATIENT CHARACTERISTICS:~Inclusion criteria:~* ECOG performance status 0-2~* WBC ≥ 4,000/mm\^3~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL~* Creatinine ≤ 130 µmol/L~* Transaminases ≤ 5 times upper limit of normal (ULN)~* Total bilirubin ≤ 1.5 times ULN~* Alkaline phosphatase ≤ 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients of must use effective contraception~Exclusion criteria:~* Contraindication to therapy with capecitabine, oxaliplatin, cetuximab, and/or radiotherapy~* Impossible to perform translational analyses~* Uncontrolled severe illness~* Severe renal or hepatic insufficiency~* Cardiac insufficiency or symptomatic coronary disease~* Sensitive peripheral neuropathy~* Uncontrolled diabetes~* Other malignancy within the past 10 years except previously treated basal cell skin cancer or carcinoma in situ of the cervix~* Impossible to participate in study due to geographic, social, or psychiatric reasons~* Patients who are under supervision or incarcerated~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior anticancer chemotherapy or radiotherapy for this cancer~* No therapy with coumarin anticoagulants, phenytoin, sorivudine, brivudine, antacids, or allopurinol~* No concurrent participation in another therapeutic study or receiving another experimental drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of AIS~* Skeletally immature (Risser grade 0, 1, or 2)~* Pre-menarchal or post-menarchal by no more than 1 year~* Primary Cobb angle between 20 and 40 degrees~* Curve apex caudal to T7 vertebrae~* Physical and mental ability to adhere to bracing protocol~* Ability to read and understand English, Spanish, or French~* Documented insurance coverage and/or personal willingness to pay for treatment~Exclusion Criteria:~* Diagnosis of other musculoskeletal or developmental illness that might be responsible for the spinal curvature~* History of previous surgical or orthotic treatment for AIS

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Brace (Type: ACTIVE_COMPARATOR): This study involves full-time, rigid TLSO's only. Braced subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning. Orthotic evaluations are conducted every 6 months as as necessary to maintain brace fit and function.
- Observation (Type: ACTIVE_COMPARATOR): Observation. Observed subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy